Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine

Journal of Virology

Volumn 89, Issue 6, 2015, Pages 3421-3426

  Cox, Andrew ^a   Baker, Steven F ^a   Nogales, Aitor ^a   Martínez Sobrido, Luis ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NONSTRUCTURAL PROTEIN 1; LIVE VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GENE MUTATION; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA VIRUS; LOW DRUG DOSE; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REVERSE GENETICS; SITE DIRECTED MUTAGENESIS; VIRUS REPLICATION; ANIMAL; CLASSIFICATION; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; VIROLOGY;

MURINAE; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; VACCINES, ATTENUATED;

EID: 84923166279     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02636-14     Document Type: Article

References (30)

1. Maassab H. 1969. Biologic and immunologic characteristics of coldadapted influenza virus. J Immunol 102:728-732.
2. Maassab H. 1967. Adaptation and growth characteristics of influenza virus at 25°C. Nature 213:612-614. http://dx.doi.org/10.1038/213612a0.
3. Snyder M, Betts R, DeBorde D, Tierney E, Clements M, Herrington D, Sears S, Dolin R, Maassab H, Murphy B. 1988. Four viral genes inde-pendently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol 62:488-495.
4. Cox N, Kitame F, Kendal A, Maassab H, Naeve C. 1988. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 167:554-567.
5. Belshe R, Ambrose C, Yi T. 2008. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 26(Suppl 4):D10-D16. http://dx.doi.org/10.1016/j.vaccine.2008.06.083.
6. Ambrose C, Dubovsky F, Yi T, Belshe R, Ashkenazi S. 2012. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis 31:2549-2557. http://dx.doi.org/10.1007/s10096-012-1595-9.
7. Zhou B, Li Y, Speer S, Subba A, Lin X, Wentworth D. 2012. Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine 30:3691-3702. http://dx.doi.org/10.1016/j.vaccine.2012 .03.025.
8. Jin H, Zhou H, Lu B, Kemble G. 2004. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from coldadapted A/Ann Arbor/6/60. J Virol 78:995-998. http://dx.doi.org/10.1128/JVI.78.2.995-998.2004.
9. Suguitan A, McAuliffe J, Mills K, Jin H, Duke G, Lu B, Luke C, Murphy B, Swayne D, Kemble G, Subbarao K. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3:e360. http://dx.doi.org/10.1371/journal.pmed .0030360.
10. Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. 2008. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 26:4940-4946. http://dx.doi .org/10.1016/j.vaccine.2008.07.013.
11. Martínez-Sobrido L, Garcìa-Sastre A. 2010. Generation of recombinant influenza virus from plasmid DNA. J Vis Exp 2010:e2057. http://dx.doi .org/10.3791/2057.
12. Nogales A, Baker S, Ortiz-Riano E, Dewhurst S, Topham DJ, Martínez-Sobrido L. 2014. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development. J Virol 88:10525-10540. http://dx .doi.org/10.1128/JVI.01565-14.
13. Grimm D, Staeheli P, Hufbauer M, Koerner I, Martínez-Sobrido L, Solórzano A, García-Sastre A, Haller O, Kochs G. 2007. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci U S A 104:6806-6811. http://dx.doi.org/10.1073/pnas.0701849104.
14. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 27:493-497.
15. Cha T, Kao K, Zhao J, Fast P, Mendelman P, Arvin A. 2000. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38:839-845.
16. Klein M, Conn C, Kluger M. 1992. Behavioral thermoregulation in mice inoculated with influenza virus. Physiol Behav 52:1133-1139. http://dx .doi.org/10.1016/0031-9384(92)90472-E.
17. Carter N, Curran M. 2011. Live attenuated influenza vaccine (FluMist; Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71:1591-1622. http://dx.doi.org/10.2165/11206860-000000000-00000.
18. Kilbourne E. 1969. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ 41:643-645.
19. Margine I, Krammer F, Hai R, Heaton N, Tan G, Andrews S, Runstadler J, Wilson P, Albrecht R, Garcìa-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435-10446. http://dx.doi.org/10 .1128/JVI.01715-13.
20. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10 .1016/j.coviro.2013.07.007.
21. Krammer F, Hai R, Yondola M, Tan G, Leyva-Grado V, Ryder A, Miller M, Rose J, Palese P, Garcìa-Sastre A, Albrecht R. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-3442. http://dx.doi.org/10.1128/JVI.03004-13.
22. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. 2013. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med 5:198ra107. http://dx.doi.org/10.1126/scitranslmed.3006637.
23. Oster G, Weycker D, Edelsberg J, Nichol K, Klein J, Belshe R. 2010. Benefits and risks of live attenuated influenza vaccine in young children. Am J Manag Care 16:e325-e344. http://www.ajmc.com/publications/issue/2010/2010-09-vol16-n09/AJMC_10sep_Oster_Excl_e235to44.
24. Chen G, Lamirande E, Jin H, Kemble G, Subbarao K. 2010. Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. Virology 398:109-114. http://dx.doi .org/10.1016/j.virol.2009.12.003.
25. Belshe R, Toback S, Yi T, Ambrose C. 2010. Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses 4:141-145. http://dx.doi.org/10.1111/j.1750-2659 .2009.00124.x.
26. Ambrose C, Wu X, Belshe R. 2010. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 29:806-811. http://dx.doi.org/10.1097/INF .0b013e3181e2872f.
27. Grohskopf LA, Olsen SJ, Sokolow LZ, Bresee JS, Cox NJ, Broder KR, Karron RA, Walter EB. 2014. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep 63:691-697. http://dx.doi.org/10.1111/ajt.13065.
28. Garaigorta U, Falson AM, Ortin J. 2005. Genetic analysis of influenza virus NS1 gene: a temperature-sensitive mutant shows defective formation of virus particles. J Virol 79:15246-15256. http://dx.doi.org/10.1128/JVI.79.24.15246-15257.2005.
29. Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. 2013. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A 110:9481-9486. http://dx.doi.org/10.1073/pnas.1307473110.
30. Baker S, Guo H, Albrecht R, Garcìa-Sastre A, Topham D, Martínez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J Virol 87:8591-8605. http://dx.doi.org/10.1128/JVI.01081-13.